TY  - BOOK
AU  - Parveen,Shama
TI  - The COVID-19 Pandemic: Epidemiology, Molecular Biology and Therapy
SN  - 9789811481871
AV  - RA644.C67 C68 2021 
U1  - 614.592414 
PY  - 2021///
CY  - Singapore
PB  - Bentham Science Publishers
KW  - Coronavirus infections
KW  - Electronic books
N1  - Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- An Introduction to Coronavirus Disease 2019 (COVID-19) -- Shama Parveen1,* and Sher Ali2 -- INTRODUCTION -- MORPHOLOGY, GENOME, PROTEINS AND VIRAL REPLICATION -- STRUCTURAL PROTEINS -- GLOBAL EPIDEMIOLOGY AND TRANSMISSION -- RISK FACTORS -- CLINICAL SYMPTOMS AND MANAGEMENT -- HOST IMMUNE RESPONSE AND PATHOGENESIS -- DIAGNOSTICS -- THERAPEUTICS (ANTIVIRALS AND NATURAL COMPOUNDS) -- VACCINE DEVELOPMENT -- CORONA WARRIORS -- SOCIO-ECONOMIC-ENVIRONMENTAL IMPACT -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Morphology, Genomic Organization, Proteins and Replication of SARS-CoV-2 -- Nazim Khan1, Arshi Islam1, Abu Hamza1, Zoya Shafat1, Asimul Islam1, Anwar Ahmed2,3 and Shama Parveen1,* -- INTRODUCTION -- VIRAL MORPHOLOGY -- GENOMIC ORGANIZATION -- STRUCTURAL PROTEINS -- Spike Protein (S-protein) -- Envelope Protein (E-protein) -- Membrane Protein (M-protein) -- Nucleocapsid (N-protein) -- NON-STRUCTURAL PROTEINS -- VIRAL GENOME REPLICATION -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Structural Protein Genes of SARS-CoV-2: Comprehensive Molecular Characterization -- Zoya Shafat1, Syed Abuzar Raza Rizvi2, Mohammad Misbah Urrehmaan1,2, Ayesha Tazeen1, Priyanka Sinha1, Anwar Ahmed3,4 and Shama Parveen1,* -- INTRODUCTION -- MATERIALS AND METHODS -- Sequences -- Compositional Properties -- Relative Synonymous Codon Usage (RSCU) -- Physiochemical Characterization -- Phylogenetic Analyses -- Dataset I -- Dataset II -- Dataset III -- Gene Ontology (GO) -- Mutational Analysis -- Selection Pressure Analysis -- Analysis of Entropy of Amino Acid Sequences -- RESULTS -- Nucleotide Composition Analysis -- S Gene -- E Gene; M Gene -- N Gene -- U- and A-ending Codons are Preferred in Coding Sequences -- S Gene -- E Gene -- M Gene -- N Gene -- Analysis of Protein Sequences -- Spike Protein -- Envelope Protein -- Membrane Protein -- Nucleocapsid Protein -- Phylogenetic Analysis -- Full Genome of Coronaviruses -- Structural Protein Genes of Coronaviruses -- Structural Protein Genes of Novel Coronaviruses (SARS-CoV-2) -- Computer Predicted Features -- Subcellular Localization Prediction with Functional Annotation -- Prediction of Effect of Mutations on Protein Function -- Helical Wheel Plot Analysis -- Analysis of Positive Selection -- S Dataset -- E Dataset -- M Dataset -- N Dataset -- Analysis of Entropy of Amino Acid Sequences -- DISCUSSION -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Codon Based Characterization of S2 Subunit of Severe Acute Respiratory Syndrome-Related Coronaviruses -- Arshi Islam1, Nazish Parveen1, Md. Shakir Hussain Haider1, Ravins Dohare1, Anwar Ahmed2,3, Sher Ali1,4 and Shama Parveen1,* -- INTRODUCTION -- METHODOLOGY -- Data Collection and Sequence Alignment -- Phylogenetic Analysis -- Selection Pressure Analyses -- Analysis of Shannon Entropy -- Glycosylation Analysis -- RESULTS -- Phylogenetic Analysis and Genetic Distance Estimation -- Selection Pressure Analysis -- Shannon Entropy Analysis -- N-linked and O-linked Glycosylation -- DISCUSSION -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Global Epidemiology and Transmission of COVID-19 -- Md. Wasim Khan1,#, Sajda Ara1,#, Farah Deeba1, Ayesha Tazeen1, Nasir Salam2, Irshad H. Naqvi3 and Shama Parveen1,* -- INTRODUCTION -- THE SPREAD -- INCREASE IN INFECTIVITY OF SARS-COV-2 -- THE SPILLOVER ZOONOTIC EVENTS -- TRANSMISSION -- Droplet and Aerosol Mediated Transmission; Airborne Transmission -- Faecal Transmission -- Vertical Transmission -- Fomites Transmission -- Familial Transmission -- Nosocomial Transmission -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFRENCES -- Risk Factors for Severe Covid-19 Disease -- Mohammad Misbah Urrehmaan1,2, Abu Hamza2, Zoya Shafat2, Saba Parveen2, Saima Wajid1,* and Shama Parveen2,* -- INTRODUCTION -- RISK FACTORS FOR SEVERE COVID-19 INFECTION -- Age Distribution -- Gender -- Blood Groups -- Comorbid Conditions -- Pre-natal Transmission -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Clinical Manifestations, Treatment, Immune Response and Pathogenesis of Covid-19 -- Irshad H. Naqvi1,*, Md. Imam Faizan2,3, Mohammad Islamuddin2, Mohd Abdullah1, Arpita Rai4 and Shama Parveen2,* -- INTRODUCTION -- CLINICAL MANIFESTATIONS -- Incubation Period -- Transmission of Disease -- Quarantine and Isolation -- Peculiar Course of COVID-19 -- CLINICAL MANAGEMENT -- Oxygen Therapy: The First Step -- Symptomatic or Pre-symptomatic Infection -- Mild Illness -- Moderate Illness -- Clinical Management of Moderate Disease -- SEVERE CASES MANAGEMENT -- Urgent Supportive Therapy with Dedicated Monitoring -- Management of Respiratory Failure with Acute Respiratory Distress Syndrome (ARSD) -- Management of Extrapulmonary Manifestations and Systemic Complications -- Management of Septic Shock -- Other Therapeutic Measures -- NEW INVESTIGATIONAL THERAPIES -- Anti-Viral Drugs -- Tocilizumab -- Hydroxychloroquine -- Anticoagulant -- Convalescent Plasma -- Dexamethasone -- IMMUNE RESPONSE IN COVID-19 -- Innate Immune Response -- Adaptive Immune Response -- Potential Immune Evasion -- PATHOGENESIS -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES; COVID-19: Current Diagnostic Approaches -- Anwar Ahmed1,2,*, Fahad N. Almajhdi1,5, Md. Imam Faizan3,4, Tanveer Ahmad3 and Shama Parveen4,* -- INTRODUCTION -- SAMPLE COLLECTION -- REAL-TIME REVERSE TRANSCRIPTASE-PCR (RT-PCR) -- LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) -- SEROLOGICAL DIAGNOSIS -- RAPID DIAGNOSTIC TEST (RDT) -- ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) -- CHEMILUMINESCENT IMMUNOASSAY (CLIA) -- NEUTRALIZATION ASSAY (NA) -- RAPID ANTIGEN DETECTION TEST (RADT) -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Natural Compounds as Potential Therapeutic Agents against COVID-19 -- Ayesha Tazeen1, Farah Deeba1, Zoya Shafat1, Md. Imam Faizan1,2, Maryam Sarwat3, Mohammad Khalid Parvez4 and Shama Parveen1,* -- INTRODUCTION -- SIGNIFICANCE OF PLANTS DERIVED COMPOUNDS AS ANTIVIRALS -- ANTIVIRAL ACTIVITY OF SELECTED NATURAL COMPOUNDS AGAINST SARS-COV-2 -- FLAVONOIDS -- Myricitrin -- Baicalin -- Hesperidin -- Theaflavin -- Quercetagetin -- Apigenin -- Glabridin -- TERPENES AND TERPENOIDS -- CURCUMINOIDS -- TANNIN -- PROMISING ANTIVIRAL POTENTIALS OF PLANTS -- Camellia Sinensis (Black/Oolong/Green Tea) -- Vitis vinifera (Grapevine or Black grapes) -- Malus domestica (Apple) -- Azadirachta indica (Neem) -- Glycyrrhiza glabra (Licorice) -- Nigella sativa (Black Seed) -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Drug Repurposing Candidates and Therapeutic Approaches towards the Treatment of COVID-19 -- Arshi Islam1, Nazish Parveen1, Abu Hamza1, Nazim Khan1, Syed Naqui Kazim1, Anwar Ahmed2,3 and Shama Parveen1,* -- INTRODUCTION -- The Available Therapeutic Options -- Strategies for the Development of an Antiviral Drug -- REMDESIVIR -- LOPINAVIR/RITONAVIR (LPV/RTV) -- CHLOROQUINE/HYDROXYCHLOROQUINE -- FAVIPIRAVIR; UMIFENOVIR (ARBIDOL) -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- COVID-19 Vaccine Development: Challenges and Current Scenarios -- Nazish Parveen1, Arshi Islam1, Nazim Khan1, Anwar Ahmed2,3, Irshad H. Naqvi4 and Shama Parveen1,* -- INTRODUCTION -- VACCINES -- OBSTACLES IN THE IMPLEMENTATION OF COVID-19 VACCINE -- ANTIGEN SELECTION FOR VACCINE DEVELOPMENT -- ONGOING VACCINE DEVELOPMENT FOR COVID-19 -- Viral Vector Vaccine -- Sputnik-V (Approved for Early Use) -- Ad5-nCoV (Approved for Limited Use) -- AZD1222 -- Janssen Vaccine -- GRAd-COV2 -- LV-SMENP-DC -- aAPC -- Whole Virus Vaccines -- CoronaVac (Approved for Limited Use) -- Inactivated Novel Coronavirus Pneumonia Vaccine -- BBIBP-CorV -- Inactivated SARS-CoV-2 Vaccine -- COVAXIN -- QazCovid -- Nucleic acid vaccines -- mRNA-1273 -- BNT162 -- Self-amplifying RNA Vaccine for COVID-19 -- CVnCoV -- GX-19 -- INO-4800 DNA Vaccine -- AG0301-COVID19 -- bacTRL-Spike -- Zydus Cadila DNA Vaccine -- Subunit Vaccines -- Recombinant subunit vaccine for COVID-19 -- NVX-CoV2373 -- COVAX-19 -- SCB-2019 -- Soberana1 -- EpiVacCorona -- Virus Like Particle (VLP) Based Vaccine -- Tuberculosis Vaccine in Clinical Trial -- BCG vaccine -- VPM1002 Vaccine -- Vaccine Candidates in Preclinical Trial -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Subject Index -- Back Cover
UR  - https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6512661
ER  -